Loading...
•
Jun 30, 2021
Longeveron Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Longeveron Inc. reported revenue of $0.5 million and a net loss of $5.0 million for the second quarter of 2021. The company's cash on hand was $16.8 million, expected to be sufficient to cover expenses through at least the fourth quarter of 2022.
Announced encouraging top-line results from Phase 2b Aging Frailty trial.
Anticipate announcing top-line results from Phase 1/2 Aging Frailty “HERA” trial this quarter.
Anticipate initiation of a Phase 2 Alzheimer’s disease trial and a Phase 2 Japan Aging Frailty trial later this year.
First subject was dosed this past June in the Phase 2 Hypoplastic Left Heart Syndrome trial.
Revenue by Segment
Forward Guidance
Based on the Company’s current operating plan and financial resources, we believe that our existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...